Advertisement

Fabry Disease pp 245-257 | Cite as

Neurological Manifestations in Fabry Disease

  • Arndt RolfsEmail author
  • Ales Dudesek
  • Jan Lukas
  • Tobias Böttcher
Chapter

Abstract

Neurological manifestations of Fabry disease occur in both the peripheral nervous system (PNS) and central nervous system (CNS), with globotriaosylceramide (Gb3) accumulation in neurons, Schwann cells and dorsal root ganglia. The abnormal Gb3 accumulation in neurons appears to have little clinical consequence on the natural history of Fabry disease. The vascular change in Fabry disease is considered to be responsible for increased regional cerebral blood flow (rCBF) documented in PET scans, especially in the posterior circulation. There is clear evidence for an increased number of lacunar infarctions, predominantly periventricular, as well as small cortical infarcts – in females as well as in males. However, the pathogenesis of Fabry vasculopathy remains mostly unclear, but is based on the combination of endothelial dysfunction and abnormal function control of the vessels. It is widely accepted that cerebral hyperperfusion, predominantly in the posterior cerebral circulation is an important cornerstone in the pathophysiology of stroke in Fabry disease. Additionally, inflammation seems to have an influence on the progress of the vasculopathy in Fabry disease. The majority of Fabry stroke patients both in the hemizygote and the heterozygote groups present symptoms and clinical signs of vertebrobasilar ischemia. Consequently, vertigo/dizziness, diplopia, dysarthria, nystagmus, ataxia are the most frequent symptoms in stroke patients with Fabry.

Keywords

Cerebral hyperfusion Stroke Lacunar infarcts Pulvinar sign Enzyme replacement therapy Cerebrovascular symptoms Hearing loss Pain 

References

  1. 1.
    Grewal RP (1994) Stroke in Fabry’s disease. J Neurol 241:153–156PubMedCrossRefGoogle Scholar
  2. 2.
    Rolfs A, Böttcher T, Zschiesche M et al (2005) High prevalence of Fabry disease in young stroke patients. Lancet 366:1794–1796PubMedCrossRefGoogle Scholar
  3. 3.
    Schiffman R, Ries M (2005) Fabry’s disease—an important risk factor for stroke. Lancet 366:1754–1756CrossRefGoogle Scholar
  4. 4.
    Crutchfield KE, Patronas NJ, Dambrosia JM et al (1998) Quantitative analysis of cerebral vasculopathy in patients with Fabry disease. Neurology 50:1746–1749PubMedCrossRefGoogle Scholar
  5. 5.
    Fellgiebel A, Albrecht J, Dellani PR et al (2007) Quantification of brain tissue alterations in Fabry disease using diffusion tensor imaging. Acta Paediatr Suppl 96:33–36PubMedCrossRefGoogle Scholar
  6. 6.
    Takanashi J, Barkovich AJ, Dillon WP et al (2003) T1 hyperintensity in the pulvinar: key imaging feature for diagnosis of Fabry disease. AJNR Am J Neuroradiol 24:916–921PubMedGoogle Scholar
  7. 7.
    Moore DF, Ye F, Schiffmann R, Butman JA (2003) Increased signal intensity in the pulvinar on T1-weighted images: a pathognomonic MR imaging sign of Fabry disease. Am J Neuroradiol 24:1096–1101PubMedGoogle Scholar
  8. 8.
    Burlina AP, Manara R, Caillaud C et al (2008) The pulvinar sign: frequency and clinical correlations in Fabry disease. J Neurol 255:738–744PubMedCrossRefGoogle Scholar
  9. 9.
    Hilz MJ, Kolodny EH, Brys M et al (2004) Reduced cerebral blood flow velocity and impaired cerebral autoregulation in patients with Fabry disease. J Neurol 251:564–570PubMedCrossRefGoogle Scholar
  10. 10.
    Moore DF, Scott LTC, Gladwin MT et al (2001) Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease. Reversal by enzyme replacement therapy. Circulation 104:1506–1512PubMedCrossRefGoogle Scholar
  11. 11.
    Moore D, Kaneski CR, Askari H et al (2007) The cerebral vasculopathy of Fabry disease. J Neurol Sci 257:258–263PubMedCrossRefGoogle Scholar
  12. 12.
    Altarescu G, Moore DF, Pursley R et al (2001) Enhanced endothelium-dependent vasodilation in Fabry disease. Stroke 32:1559–1562PubMedCrossRefGoogle Scholar
  13. 13.
    Fellgiebel A, Muller MJ, Ginsberg L (2006) CNS manifestations of Fabry’s disease. Lancet Neurol 5:791–795PubMedCrossRefGoogle Scholar
  14. 14.
    Eyskens FJ, De Deyn PP (2009) Belgian Fabry stroke study (BEFAS): a national, multicentre, prospective study on the prevalence of Fabry disease in young stroke patients with stroke. Mol Genet Metabol 98:1–2CrossRefGoogle Scholar
  15. 15.
    Sims K, Politei J, Banikazemi M et al (2009) Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry. Stroke 40(3):788–794PubMedCrossRefGoogle Scholar
  16. 16.
    Moore DF, Herscovitch P, Schiffmann R (2001) Selective arterial distribution of cerebral hyper-perfusion in Fabry disease. J Neuroimaging 11:303–307PubMedCrossRefGoogle Scholar
  17. 17.
    Mitsias P, Levine SR (1996) Cerebrovascular complications of Fabry’s disease. Ann Neurol 40:8–17PubMedCrossRefGoogle Scholar
  18. 18.
    Taglianini F, Pietrini V, Gemignani F, Lechi A, Pallini R, Federico A (1982) Anderson-Fabry’s disease: neuropathological and neurochemical investigation. Acta Neuropathol (Berl) 56:93–98CrossRefGoogle Scholar
  19. 19.
    Kaye EM, Kolodny EH, Logigian EL et al (1988) Nervous system involvement in Fabry’s disease: clinicopathological and biochemical correlation. Ann Neurol 23:505–509PubMedCrossRefGoogle Scholar
  20. 20.
    Gavazzi C, Borsini W, Guerrini L et al (2006) Subcortical damage and cortical functional changes in men and women with Fabry disease: a multifaceted MR study. Radiology 241:492–500PubMedCrossRefGoogle Scholar
  21. 21.
    Resta M, Gentile A, Cuonzo FD (1984) Clinical-angiographic correlations in 132 patients with megadolichovertebrobasilar anomaly. Neuroradiology 26:213–216PubMedCrossRefGoogle Scholar
  22. 22.
    Yu Y, Mosely IF, Pullicino P et al (1982) The clinical picture of ectasia of the intracerebral arteries. J Neurol Neurosurg Psychiatry 45:29–36PubMedCrossRefGoogle Scholar
  23. 23.
    Fellgiebel A, Keller I, Marin D et al (2009) Diagnostic utility of different MRI and MR angiography measures in Fabry disease. Neurology 72(1):63–68PubMedCrossRefGoogle Scholar
  24. 24.
    DeGraba T, Azhar S, Dignat-George F et al (2000) Profile of endothelial and leukocyte activation in Fabry patients. Ann Neurol 47:229–233PubMedCrossRefGoogle Scholar
  25. 25.
    Mehta A, Ricci R, Widmer U et al (2004) Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Europ J Clin Invest 34:236–242PubMedCrossRefGoogle Scholar
  26. 26.
    Mehta A, Clarke JT, Giugliani R et al (2009) Natural course of Fabry disease: changing pattern of causes of death in FOS – Fabry Outcome Survey. J Med Genet 46(8):548–552PubMedCrossRefGoogle Scholar
  27. 27.
    Leech N, Johnson K (2003) Enzyme replacement treatment in “cerebrovascular” Fabry disease – when is it too late? The 4th European round table on Fabry disease. Expectations of enzyme replacement therapy, Oct 17–18, 2003, Munich, GermanyGoogle Scholar
  28. 28.
    Suresh S, Thompson L, Kenny M et al (2003) The effect of enzyme replacement therapy on the neurological complications of Anderson Fabry disease. The 4th European round table on Fabry disease. Expectations of enzyme replacement therapy, Oct 17–18, 2003, Munich, GermanyGoogle Scholar
  29. 29.
    Yamadera M, Yokoe M, Beck G et al (2009) Amelioration of white-matter lesions in a patient with Fabry disease. J Neurol Sci 279(1–2):118–120PubMedCrossRefGoogle Scholar
  30. 30.
    Callegaro D, Kaimen-Maciel DR (2006) Fabry disease as a differential diagnosis of MS. Int MS J 13(1):27–30PubMedGoogle Scholar
  31. 31.
    Saip S, Uluduz D, Erkol G (2007) Fabry disease mimicking multiple sclerosis. Clin Neurol Neurosurg 109(4):361–363PubMedCrossRefGoogle Scholar
  32. 32.
    Invernizzi P, Bonometti MA, Turri E et al (2008) A case of Fabry disease with central nervous system (CNS) demyelinating lesions: a double trouble? Mult Scler 14(7):1003–1006PubMedCrossRefGoogle Scholar
  33. 33.
    Keilmann A, Hajioff D, Ramaswami U, on behalf of the FOS Investigators (2009) Ear symptoms in children with Fabry disease: data from the Fabry Outcome Survey. J Inherit Metab Dis 32(6):739–744PubMedCrossRefGoogle Scholar
  34. 34.
    Palla A, Hegemann S, Widmer U et al (2007) Vestibular and auditory deficits in Fabry disease and their response to enzyme replacement therapy. J Neurol 254(10):1433–1442PubMedCrossRefGoogle Scholar
  35. 35.
    Ries M, Kim HJ, Zalewski CK et al (2007) Neuropathic and cerebrovascular correlates of hearing loss in Fabry disease. Brain 130(Pt 1):143–150PubMedGoogle Scholar
  36. 36.
    Hajioff D, Enever Y, Quiney R et al (2003) Hearing loss in Fabry disease: the effect of agalsidase alfa replacement therapy. J Inherit Metab Dis 26(8):787–794PubMedCrossRefGoogle Scholar
  37. 37.
    Torvin Møller A, Winther Bach F, Feldt-Rasmussen U et al (2009) Functional and structural nerve fiber findings in heterozygote patients with Fabry disease. Pain 145(1–2):237–245PubMedCrossRefGoogle Scholar
  38. 38.
    Rodrigues LG, Ferraz MJ, Rodrigues D et al (2009) Neurophysiological, behavioral and morphological abnormalities in the Fabry knockout mice. Neurobiol Dis 33(1):48–56PubMedCrossRefGoogle Scholar
  39. 39.
    Maag R, Binder A, Maier C et al (2008) Detection of a characteristic painful neuropathy in Fabry disease: a pilot study. Pain Med 9(8):1217–1223PubMedCrossRefGoogle Scholar
  40. 40.
    Laaksonen SM, Röyttä M, Jääskeläinen SK, Kantola I, Penttinen M, Falck B (2008) Neuropathic symptoms and findings in women with Fabry disease. Clin Neurophysiol 119(6):1365–1372PubMedCrossRefGoogle Scholar
  41. 41.
    Hoffmann B, Beck M, Sunder-Plassmann G et al (2007) Nature and prevalence of pain in Fabry disease and its response to enzyme replacement therapy–a retrospective analysis from the Fabry Outcome Survey. Clin J Pain 23(6):535–542PubMedCrossRefGoogle Scholar

Copyright information

© Springer Netherlands 2010

Authors and Affiliations

  • Arndt Rolfs
    • 1
    Email author
  • Ales Dudesek
    • 2
  • Jan Lukas
    • 1
  • Tobias Böttcher
    • 1
  1. 1.Medical FacultyAlbrecht-Kossel-Institute for Neuroregeneration, University of RostockRostockGermany
  2. 2.Department of NeurologyUniversity of RostockRostockGermany

Personalised recommendations